Search Results - matthew+rettig

1 Results

Sort By:

2017-094: Inhibitors of the N-Terminal Domain of the Androgen Receptor

SUMMARYUCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.BACKGROUNDProstate...

Published: 7/19/2023 | Inventor(s): Matthew Rettig, Michael Jung

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)